UNIVERSITY of York

This is a repository copy of *Disruption of the GDP-mannose synthesis pathway in Streptomyces coelicolor results in antibiotic hyper-susceptible phenotypes*.

White Rose Research Online URL for this paper:
https://eprints.whiterose.ac.uk/128230/

Version: Accepted Version

Article:

Howlett, Robert, Anttonen, Katri, Read, Nicholas et al. (1 more author) (2018) Disruption of the GDP-mannose synthesis pathway in Streptomyces coelicolor results in antibiotic hyper-susceptible phenotypes. Microbiology (Reading, England). ISSN 1465-2080

https://doi.org/10.1099/mic.0.000636

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

White Rose university consortium
Universities of Leeds, Sheffield & York

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/

Microbiology

Disruption of the GDP-mannose synthesis pathway in Streptomyces coelicolor results in antibiotic hyper-susceptible phenotypes

--Manuscript Draft--

Manuscript Number:	MIC-D-18-00002R1
Full Title:	Disruption of the GDP-mannose synthesis pathway in Streptomyces coelicolor results in antibiotic hyper-susceptible phenotypes
Article Type:	Research Article
Section/Category:	Physiology and metabolism
Corresponding Author:	Margaret CM Smith, PhD University of Leeds Leeds, West Yorkshire UNITED KINGDOM
First Author:	Robert Howlett, PhD
Order of Authors:	Robert Howlett, PhD
	Katri Anttonen, PhD
	Nicholas Read, PhD
	Margaret CM Smith, PhD
Abstract:	Actinomycete bacteria use polyprenol phosphate mannose as a lipid linked sugar donor for extra-cytoplasmic glycosyl transferases that transfer mannose to cell envelope polymers, including glycoproteins and glycolipids. We showed recently that strains of Streptomyces coelicolor with mutations in the ppm1 gene, which encodes polyprenol phosphate mannose synthase, were both resistant to phage φC31 and have greatly increased susceptibility to antibiotics that mostly act on cell wall biogenesis. Here we show that mutations in the genes encoding enzymes that act upstream of Ppm1 in the polyprenol phosphate mannose synthesis pathway can also confer phage resistance and antibiotic hyper-susceptibility. GDP-mannose is a substrate for Ppm1 and is synthesized by GDP-mannose pyrophosphorylase (GMP;ManC) which uses GTP and mannose-1-phosphate as substrates. Phosphomannomutase (PMM;ManB) converts mannose-6-phosphate to mannose-1 phosphate. S. coelicolor strains with knocked down GMP activity or with a mutation in sco3028 encoding PMM acquire phenotypes that resemble those of the ppm1- mutants i.e. φC31 resistant and susceptible to antibiotics. Differences in the phenotypes of the strains were observed, however. While the ppm1- strains have a small colony phenotype, the sco3028::Tn5062 mutants had an extremely small colony phenotype indicative of an even greater growth defect. Moreover we were unable to generate a strain in which GMP activity encoded by sco3039 and sco4238 is completely knocked out, indicating that GMP is also an important enzyme for growth. Possibly GDP-mannose is at a metabolic branch point where it is modified to supply alternative nucleotide sugar donors.

Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation

Manuscript Including References (Word document) Click here to download Manuscript Including References (Word document) ManC_B paper_revised_clean.docx

1 **Disruption of the GDP-mannose synthesis pathway in *Streptomyces coelicolor***

2 **results in antibiotic hyper-susceptible phenotypes**

3 Robert Howlett [a], Katri Anttonen [b], Nicholas Read [a], and Margaret C.M Smith [a,b, #]

4

5 [a] Department of Biology, University of York, York, United Kingdom;

6 [b] Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom;

7 [#]Address correspondence to Margaret C.M. Smith, Maggie.smith@york.ac.uk

8

9 Running Title: *S. coelicolor* strains disrupted in the synthesis of GDP-mannose

10

11 Abbreviations; Ppm1; polyprenol phosphate mannose synthase, PMM;

12 Phosphomannomutase, GMP; GDP-mannose pyrophosphorylase, PGM;

13 phosphoglucomutase, MESG; 2-amino-6-mercapto-7-methylpurine ribonucleoside,

14 PNP; purine nucleoside phosphorylase, SMMS; supplemented minimal medium

15 solid.

16

17

Abstract

Actinomycete bacteria use polyprenol phosphate mannose as a lipid linked sugar donor for extra-cytoplasmic glycosyl transferases that transfer mannose to cell envelope polymers, including glycoproteins and glycolipids. We showed recently that strains of *Streptomyces coelicolor* with mutations in the gene *ppm1* encoding polyprenol phosphate mannose synthase were both resistant to phage ϕC31 and have greatly increased susceptibility to antibiotics that mostly act on cell wall biogenesis. Here we show that mutations in the genes encoding enzymes that act upstream of Ppm1 in the polyprenol phosphate mannose synthesis pathway can also confer phage resistance and antibiotic hyper-susceptibility. GDP-mannose is a substrate for Ppm1 and is synthesized by GDP-mannose pyrophosphorylase (GMP;ManC) which uses GTP and mannose-1-phosphate as substrates. Phosphomannomutase (PMM; ManB) converts mannose-6-phosphate to mannose-1 phosphate. *S. coelicolor* strains with knocked down GMP activity or with a mutation in *sco3028* encoding PMM acquire phenotypes that resemble those of the *ppm1*$^-$ mutants i.e. ϕC31 resistant and susceptible to antibiotics. Differences in the phenotypes of the strains were observed, however. While the *ppm1*$^-$ strains have a small colony phenotype, the *sco3028*::Tn*5062* mutants had an extremely small colony phenotype indicative of an even greater growth defect. Moreover we were unable to generate a strain in which GMP activity encoded by *sco3039* and *sco4238* is completely knocked out, indicating that GMP is also an important enzyme for growth. Possibly GDP-mannose is at a metabolic branch point where it is modified to supply alternative nucleotide sugar donors.

43 **Introduction**

44 *Streptomyces* spp. are prolific producers of secondary metabolites, many with potent
45 antibiotic activity. In nature *Streptomyces* spp. produce antibiotics either to inhibit
46 competitors thus providing the producer with a growth advantage or as signalling
47 molecules in microbial communities [1, 2]. Either way *Streptomyces* bacteria are
48 constantly exposed to antibiotics produced by other soil microorganisms and
49 consequently have evolved resistance mechanisms [3]. As such *Streptomyces* spp.
50 are a model system to study how the mechanisms of antibiotic resistance evolve in
51 an environmental organism.

52

53 We recently showed that strains of *S. coelicolor* lacking the ability to synthesise
54 polyprenol phosphate mannose due to mutations in polyprenol phosphate mannose
55 synthase (Ppm1) were hyper-sensitive to multiple antibiotics (Howlett et al,
56 submitted). We used RNA-seq and Raman spectroscopy to demonstrate that the
57 strains had undergone changes to the membrane phospholipids, with possible
58 subsequent changes to membrane functions. Polyprenol phosphate mannose
59 synthase, Ppm1, transfers mannose from GDP-mannose to polyprenol phosphate
60 (Fig. 1). Previously we demonstrated that the synthesis of polyprenol phosphate
61 mannose was entirely dependent on membrane associated Ppm1 [4].

62

63 Polyprenol phosphate mannose is the mannose donor for extracytoplasmic glycosyl
64 transferases. One of these is a protein mannosyl transferase (Pmt), which
65 glycosylates periplasmic and membrane proteins in *Streptomyces* [4, 5]. Pmt
66 defective strains also show increased antibiotic susceptibility compared to the parent
67 strain, but to fewer antibiotics and to a lower level than the *ppm1*$^{-}$ mutants (Howlett et

68 al, submitted). Loss of protein glycosylation is therefore likely to contribute in part to
69 the antibiotic hyper susceptible phenotype of the *ppm1*$^{-}$ mutants. In addition both
70 *ppm1*$^{-}$ strains and the *pmt*$^{-}$ strains are resistant to the phage ϕC31, most likely
71 through loss of the receptor, although the exact nature of the phage receptor is still
72 unknown [5, 6].
73
74 Polyprenol phosphate mannose is likely to be a mannose donor for other cell
75 envelope macromolecules with one of these likely to be phosphoinositol mannosides
76 (PIMs) [7, 8]. In other Actinobacteria including *Mycobacterium* and *Corynebacterium*
77 spp. PIMs are precursors for the synthesis of lipoarabinomannan and lipomannan [9],
78 but neither of these polymers have been reported in *Streptomyces*. Ppm1 is an
79 essential enzyme in mycobacteria and a *ppm1*$^{-}$ strain of *Corynebacterium* is growth
80 retarded indicating the central role polyprenol phosphate mannose has in both
81 organisms [10, 11]. The protein O-glycosylation pathway is present in most
82 Actinobacteria and Pmt in Mtb has been shown to be important for virulence [12, 13].
83 In *Streptomyces coelicolor* other putative glycosyl transferases are also likely to use
84 polyprenol phosphate mannose as a sugar donor and some of these are described in
85 Howlett et al (submitted).
86
87 The role of polyprenol phosphate mannose in antibiotic resistance and the pathway
88 leading to its synthesis is addressed further in this paper (Fig. 1). D-mannose is
89 either taken up from the medium and converted by hexokinase to D-mannose-6-
90 phosphate or the latter can be produced from D-fructose-6-phosphate by
91 phosphomannoisomerase (ManA). Phosphomannomutase (ManB: PMM) then
92 converts D-mannose-6-phosphate is to D-mannose-1-phosphate which is a substrate

93 for GDP mannose pyrophosphorylase (ManC:GMP). In *Corynebacterium glutamicum*
94 deletion of the *manC* homologue (NCgl0710) conferred retarded growth and loss of
95 nearly all mannoglycans from the envelope [14]. This phenotype resembles that of
96 the *ppm1* mutant of *C. glutamicum* [10] and suggests that the ManB, ManC pathway
97 is responsible for the synthesis of GDP-mannose. We hypothesized that strains
98 containing blocks in the pathway leading to the synthesis of GDP-mannose ought to
99 be phenotypically similar to the *ppm1*$^{-}$ strains as they too will be deficient in
100 polyprenol phosphate mannose. Here we analyzed the roles of three putative *manC*
101 genes in the *S. coelicolor* genome and a *manB* gene. We show that both a GMP
102 depleted strain and a strain lacking PMM do indeed have phenotypes reminiscent of
103 the *ppm1*$^{-}$ mutants. The phenotype of the *S. coelicolor manB*$^{-}$ strains constructed
104 here varied from that reported previously for a *manB*$^{-}$ strain [15, 16]. We conclude
105 that GMP activity in *S. coelicolor* is provided by expression of two genes, *sco3039*
106 and *sco4238*. Moreover both GMP and PMM activities are part of the same metabolic
107 pathway leading to the synthesis of polyprenol phosphate mannose and ultimately to
108 glycoprotein biosynthesis in *S. coelicolor*.
109
110 **Methods**
111 *DNA manipulations*
112 Chemically competent *E. coli* cells were prepared, stored and used in the
113 transformation procedure as described previously [17]. Plasmid DNA extraction from
114 *E. coli* was performed using a Spin Miniprep Kit following the protocol supplied by the
115 manufacturer (QIAGEN). Cosmids were manipulated as described [18]. Restriction
116 enzymes and T4 ligase were obtained from New England Biolabs (NEB) and used
117 according to the manufacturer's instruction. Phusion ® High-Fidelity DNA Polymerase

118 (NEB) was employed for PCR amplification. Primers used in the present study are
119 listed (Table S1). In-fusion® HD cloning kit (Clontech) was used according to the
120 protocol supplied by the manufacturer. DNA sequencing (Sanger) was outsourced to
121 Source Bioscience.

122 *Plasmid, cosmid and strain constructions*

123 A list of plasmids and cosmids used in this work is provided (Table 1). Plasmid
124 pRH01 was produced by cloning of the PCR amplified product from primers RH11
125 and RH12 and J1929 genomic DNA as template, into EcoRV digested vector
126 pAV11b [19-21]. Plasmid pRH12 was produced by cloning the PCR product from
127 primers RH91 and RH92 and J1929 template into NdeI digested pIJ10257. Plasmids
128 pRH11 and pRH14 were produced similar to pRH12 but using *E.coli* DH5 α genomic
129 DNA as template and primer pairs RH93/RH94, and RH140/RH141, respectively.
130 Expression plasmids for *sco3039* (pRH06) and *sco4238* (pRH07) were produced
131 through the ligation of XhoI and NdeI digested PCR products from primers pairs
132 RH71/RH72, and RH73/RH74, respectively, and *S. coelicolor* J1929 template DNA,
133 into XhoI and NdeI digested pET21a fusing both ORFs to an inframe C-terminal
134 hexa-histidine tag. All constructs were confirmed as correct through Sanger
135 sequencing performed by Source Bioscience.

136 The apramycin resistance markers within the Tn*5062* transposon of StD8A.2.D12
137 and St1A8A.1.B09 were replaced with spectinomycin and hygromycin markers,
138 respectively, using the REDIRECT methodology [18]. Cosmids were introduced into
139 *S. coelicolor* J1929 by conjugation and resistant exconjugants were selected
140 according to the marker on Tn*5062* (apramycin, spectinomycin or hygromycin
141 resistance). Those that had undergone a double cross over recombination event
142 were identified initially as they lost the marker (kanamycin resistance) on the cosmid

143 vector backbone. Presence of the interrupted allele and loss of the wild type allele

144 was confirmed by PCR and Southern blotting.

145

146 *Phage sensitivity assays*

147 Plaque assays were performed as described [22]. Briefly Difco nutrient agar

148 supplemented with 10 mM $MgSO_4$ and 8 mM Ca $(NO_3)_2$ were inoculated with

149 dilutions of ϕC31 *Δc25* (clear plaque) phage [23] and then overlayed with soft nutrient

150 agar containing approximately 1 x 10^7 spores of the desired test strain. The streak

151 plate assay was performed using square 10 cm plates containing Difco nutrient agar

152 (10 mM $MgSO_4$ and 8 mM Ca $(NO_3)_2$). One half of the plate was inoculated with 100

153 □l of ϕC31 *Δc25* (approx 1 x 10^8 pfu/ml) and a single streak of the test spore

154 preparation was inoculated across the plate beginning on the phage-free region.

155 Plates were incubated at 30 ^oC.

156

157 *Protein expression*

158 An overnight culture of *E. coli* BL21DE3 (pRH07) in LB containing ampicillin was

159 grown at 37 ^oC and used to inoculate 2YT, which was grown to OD 0.6. IPTG (0.15

160 mM) was then added to induce expression and the culture was further incubated (22

161 ^oC for 22 hours). The bacteria were harvested by centrifugation and resuspended in

162 binding buffer (30 ml; 20 mM Tris HCl pH 7.4, 0.5M NaCl, 30 mM imidazole) and

163 sonicated. The cell lysate was cleared by centrifugation (4 ^oC, 5 minutes, 10,000g) to

164 remove unlysed cells and debris and then the supernatant was loaded onto a HiTrap

165 Ni^{2+} affinity column (AKTA Purifier). After washing with 2 column volumes of binding

166 buffer the bound protein was eluted with a gradient of increasing imidazole

167 concentration using the elution buffer (20 mM Tris HCl pH 7.4, 0.5M NaCl, 500 mM

168 imidazole). Pooled fractions were then loaded onto a desalting column to remove
169 imidazole and eluted in 20 mM Tris HCl pH 7.4, 0.5M NaCl. The protein was
170 concentrated using Vivaspin (GE healthcare) spin columns to approximately 10
171 mg/ml. Glycerol was added to a final concentration of 50% and aliquots were stored
172 at -80 ^{o}C. Protein concentration was assayed using the BioRad protein assay
173 solution and is based on the Bradford assay [24].
174
175 *GDP mannose pyrophosphorylase assays*
176 Activity was measured by monitoring the release of pyrophosphate using the
177 EnzChek® pyrophosphate assay kit (Thermofisher). Briefly the kit includes a
178 pyrophosphatase that catalyses the conversion of the pyrophosphate released from
179 the GMP activity to two equivalents of phosphate, which is then used as a substrate
180 in a reaction with 2-amino-6-mercapto-7-methylpurine ribonucleoside (MESG) and
181 purine nucleoside phosphorylase (PNP) to release ribose 1-phosphate and 2-amino-
182 6-mercapto-7-methyl-purine. The latter compound was detected
183 spectrophotometrically by absorbance at 360 nm. Assays were performed according
184 to the manufacturers instructions except that they were scaled down to enable use of
185 a 96 well plate reader (200 µl assay volume per well). GMP activity rates were
186 obtained using different nucleotides (1 mM ATP, GTP, CTP or dTTP) and sugars, (1
187 mM mannose-1-phosphate or mannose-6-phosphate) as substrates. Initial rates
188 were calculated and plotted against substrate concentration using SIGMAplot.
189
190 **Results**
191 *Identification of putative GDP-mannose pyrophosphorylases*

192 GDP-mannose, a substrate for Ppm1, is synthesized by GDP-mannose
193 pyrophosphorylase (GMP) encoded by *manC* (Fig. 1). BLAST searches of the
194 *Streptomyces coelicolor* genome with the characterised *Corynebacterium*
195 *glutamicum* GMP/ManC (encoded by NCgl0710) and *Mycobacterium tuberculosis*
196 GMP/ManC (encoded by Rv3264c) identified SCO1388, SCO3039 and SCO4238 as
197 putative GMP candidates (Fig. 2) [14]. The nucleotidyl transferase domains of all
198 three *Streptomyces* GMP/ManC candidates contain the GXGXRXnK signature motif
199 of phosphorylases, and variations on the F(V)EKP motif characteristic of the GMP
200 active site (Fig. 2) [25, 26]. SCO3039 and SCO1388 have protein domains in addition
201 to the nucleotidyl transferase domain; SCO1388 in particular appears to be a
202 bifunctional enzyme with both GMP and phophomannomutase (ManB) activity (Fig.
203 2).
204
205 *SCO3039 and SCO4238 have overlapping functions*
206
207 The *S. coelicolor* genes *sco1388*, *sco3039* and *sco4238* were disrupted by allelic
208 exchange with cosmids containing Tn*5062* in the gene of interest to produce single
209 insertion mutants RH501 (*sco1388*::Tn*5062*), SKA211 *(sco3039*::Tn*5062*) and
210 SKA311 (*sco4238*::Tn*5062*). The cosmids were obtained from the transposon
211 insertion cosmid library [27] (Table 1). Validated mutants were tested for ϕC31
212 resistance as a potential indicator for a loss of GMP/ManC activity due to a lack of
213 protein *O*-glycosylation [5, 6], but all of the mutants were still sensitive to phage
214 infection. A mild increase in blue pigment production was seen in the mutant strains
215 SKA311 (*sco4238*::Tn*5062*) and SKA211 *(sco3039*::Tn*5062*) when grown on
216 supplemented minimal media (SMM) (not shown).

217

218 Double mutants were created to assess whether there is redundancy in gene
219 function between *sco3039, sco4238* and *sco1388*. The cosmid StD8A.2.D12^{spec}
220 (*sco4238*:Tn*5062*^{spec}) was introduced into J1929 by conjugation to create the
221 spectinomycin resistant *sco4238* insertion mutant, RH25. The cosmid StE34.1.G05
222 (*sco3039*::Tn*5062*) was then introduced into RH25 by conjugation, selecting for
223 apramycin resistance. Only 8 exconjugants from several hundred that were screened
224 had the spectinomycin-resistant, apramycin-resistant, kanamycin-sensitive
225 phenotype indicative of a *sco4238::*Tn*5062*^{spec}, *sco3039::*Tn*5062* double mutant.
226 However subsequent analysis by polymerase chain reaction (PCR) to amplify the
227 genomic region containing *sco3039* showed that this gene was uninterrupted in all
228 eight candidate double mutant strains and mutations must have occurred elsewhere
229 to confer resistance to apramycin. Thus we were unable to create a simple double
230 mutant containing Tn*5062* insertions in both *sco3039* and *sco4238,* suggesting that
231 these genes share an important function for growth. Multiple *sco4238::Tn5062*^{spec}*,*
232 *sco1388::Tn5062* and *sco3039::Tn5062, sco1388::Tn5062*^{hyg} double mutant strains
233 were produced and confirmed through kanamycin sensitivity. The phenotypes of
234 these strains were no different from the individual *sco4238::Tn5062* and
235 *sco3039::Tn5062* mutants, SKA311 and SKA211, respectively. The product of
236 *sco1388* therefore probably contributes little to the total GMP activity in *S. coelicolor.*

237

238 We were able to create a strain containing both *sco4238::Tn5062*^{spec} and
239 *sco3039::Tn5062* insertions in the presence of a conditionally expressed *sco4238*.
240 Plasmid pRH01, encoding *sco4238* under the control of the anhydrotetracycline
241 (ATC) inducible promoter, *tcp830* [20], was introduced into RH25 to create strain

242 RH221 (*sco4238*::Tn*5062*^{spec}, *tcp830-sco4238, hyg*). Conjugation of StE34.1.G05
243 (*sco3039*::Tn*5062*) into RH221 in the presence of ATC resulted in multiple spec^{R},
244 apra^{R}, hyg^{R}, kan^{S} exconjugants (RH2213) that were subsequently confirmed as
245 *sco4238::*Tn*5062*^{spec}, *sco3039::*Tn*5062* double mutants through PCR. Surprisingly
246 RH2213 could grow in the absence of ATC, an observation that was at odds with our
247 inability to isolate the transposon double mutants in the absence of pRH01. Colony
248 sizes of the RH2213 strains in the absence of ATC were indistinguishable from the
249 wild type parent strain, J1929, but a significant increase in blue pigments were
250 observed compared to the single mutants RH25 (*sco4238*::Tn*5062*^{spec}) and SKA211
251 *(sco3039*::Tn*5062*)(Fig. 2B). The *tcp830* promoter has been shown by others to be
252 incompletely turned off in the absence of ATC and we propose that this is also the
253 case in our experiments [19]. It seems likely that RH2213 grown in the absence of
254 ATC has a depleted level of GMP compared to the parent strain and compared to
255 RH2213 grown in the presence of ATC.
256
257
258 *Strains depleted in the putative GMPs SCO3039 and SCO4238 are hyper*
259 *susceptible to antibiotics and partially resistant to* ϕ*C31*
260
261 Ppm1 uses GDP-mannose as a substrate and we therefore hypothesized that
262 inability to synthesize GDP-mannose, for example through GMP depletion, should
263 result in a similar phenotype to those strains deficient in Ppm1. RH2213 isolates
264 (*sco4239::Tn5062*^{spec}, *sco3039::Tn5062,* pRH01 encoding inducible *sco4238)* were
265 still able to support ϕC31 plaque formation but displayed resistance to ϕC31 on a
266 streak assay in the absence of ATC (Fig 3A).

267

268 We then tested the putative GMP deficient strains for their susceptibilities to
269 antibiotics, notably those to which the *ppm1* and *pmt* mutants were particularly
270 sensitive. *S. coelicolor* strains SKA211 and RH25 containing Tn*5062* insertions in
271 *sco3039* and *sco4238*, respectively, had the same antibiotic resistances as the
272 parent strain J1929. However RH2213, with depleted levels of GMP in the absence
273 of ATC, was highly susceptible to antibiotics, strongly resembling the phenotypes of
274 the *ppm1* mutants (Fig. 3B). The phenotypes of the GMP depleted mutants indicate
275 that *sco3039* and *sco4238* provide the majority of the GMP activity in *S. coelicolor*.

276

277 *SCO4238 encodes a highly specific GDP-mannose pyrophosphorylase activity*

278

279 To confirm the phenotypes mentioned above were due to a depletion of GMP activity
280 in RH2213, *sco4238* and *sco3039* were overexpressed in *E. coli* in order to assay
281 GMP activity on purified proteins. Overproduced SCO4238 showed high GMP activity
282 (Fig. 4). The enzyme was highly specific for GTP and D-mannose-1-phosphate
283 substrates, with no or very low rates achieved with CTP, ATP and dTTP (not shown).
284 Approximately 50% activity was observed with D-mannose-6-phosphate and GTP,
285 with the Hill coefficient showing a loss of the cooperativity seen with D-mannose-1-
286 phosphate. In *Mycobacterium tuberculosis* the essential enzyme, RmlA, catalyses
287 the synthesis of dTDP-glucose, an intermediate in dTDP-rhamnose biosynthesis
288 required for the integrity of the cell wall [28]. Given the apparent essentiality of GMP
289 in *S. coelicolor* we tested whether SCO4238 had activity on glucose-1-phosphate in
290 combination with any nucleotide, including dTTP but no activity was detected.

291 Attempts to obtain soluble, active SCO3039 from several overexpression constructs
292 in *E. coli* failed (not shown).
293
294 *Strains with a mutation in the* manB *gene,* sco3028 *are also phenotypically similar to*
295 *the* ppm1 *mutants*
296 Previous work has shown that SCO3028 is a dual functioning enzyme capable of
297 phosphomannomutase (PMM, mannose-6-phosphate to mannose-1-phosphate) and
298 phosphoglucomutase (PGM, glucose-6-phosphate to glucose-1-phosphate) activity
299 [16]. The authors constructed a *manB* deletion mutant, Δ*manB,* which had increased
300 actinorhodin production and had lost chloramphenicol resistance but displayed
301 apparently similar growth to the parent strain, M145 [15, 16]. Both phenotypes of the
302 Δ*manB* strain were complemented when wild type *E. coli manB* but not *S. coelicolor*
303 *pgm* gene (*sco7443*) were introduced. Thus PMM activity was shown to be solely
304 responsible for an increase in chloramphenicol sensitivity and actinorhodin
305 production in *S. coelicolor* M145. If SCO3028 is the sole PMM enzyme in *S.*
306 *coelicolor* we would expect a similar phenotype in the *sco3028* mutant as we see for
307 the GMP depleted strains. However, Yang *et al* did not detect increased susceptibility
308 of their Δ*manB* strain to vancomycin, bacitracin or ampicillin [16].
309
310 In order to assess the phenotype of an *sco3028* mutant in our ϕC31 sensitive strain
311 *S. coelicolor* J1929, a *pglY*$^{-}$ derivative of M145 [29], the cosmid StE34.1.B03
312 (*sco3028*::Tn*5062*) was introduced into J1929 by conjugation. Exconjugants that had
313 undergone a double crossover (RHB42 strains, validated by PCR) were isolated at
314 low frequency and had an extreme small (XS) colony phenotype, even smaller than
315 the colony size seen in the *ppm1* mutant DT3017 (Fig. 5). The XS colony phenotype

316 in RHB42 could be fully restored to wild type through complementation with *S.*
317 *coelicolor sco3028 (manB),* and *Escherichia coli manB* (*cpsG*) as observed in strains
318 RHB4212 and RHB4211, respectively. RHB42 containing *Escherichia coli pgm,*
319 encoding phosphoglucomutase*,* was capable of partially restoring colony size
320 (RHB4214), suggesting it is the loss of both PMM and PGM activity that had resulted
321 in the XS colony phenotype in RHB42.
322
323 RHB42 was highly resistant to ϕC31 infection in a plaque assay, resembling phage
324 resistance in the *pmt* and *ppm1* mutants (Fig. 5A). RHB42 was also highly
325 susceptible to a number of cell wall acting antibiotics, as well as the RNA polymerase
326 targeting antibiotic, rifampicin (Fig. 5B). Phage sensitivity and antibiotic resistance
327 were restored to wild type in RHB4212 ($sco3028^{+}$) and RHB4211 ($cpsG^{+}$) but not
328 RHB4214 (pgm^{+}). No difference in chloramphenicol resistance between RHB42 and
329 J1929 was observed. These phenotypes are consistent with SCO3028 being the
330 primary PMM in *S. coelicolor* and in the same metabolic pathway that synthesizes
331 polyprenol phosphate mannose.
332
333 An increase in pigment production was recorded in RHB42, similar to that seen
334 previously following *sco3028* deletion [16] and that seen in the GMP depleted strain,
335 RH2213 (Fig. 5C). The production of blue pigment was reduced to wild type level in
336 RHB4212 ($sco3028^{+}$) and RHB4211 ($cpsG^{+}$) but not RHB4214 (pgm^{+}) (Fig. 5). To
337 further validate our observations (as they differ from those of Yang et al, [15, 16]), we
338 created two more sets of *sco3028::*Tn*5062* mutants: First we used a different Tn*5062*
339 insertion in J1929 using cosmid, STE34.2.D03, generating strain JD182 and second
340 we generated derivatives of M145 containing the Tn*5062* insertions from both

341 STE34.1.B03 and STE34.2.D03 to generate strains MD202 and MB92, respectively.
342 All three strains had an identical phenotype to RHB42 (Figs S1 and S2).
343
344 **Discussion**
345 Mannose is a component of cell envelope polymers including mannolipids,
346 phosphoinositol mannosides (PIMs) and glycoproteins in many bacteria [9, 30-32].
347 Extracytoplasmic glycosyl transferases use polyprenol phosphate mannose as the
348 lipid linked sugar donor in the biosynthesis of mannose containing polymers [4, 33].
349 The synthesis of polyprenol phosphate mannose by Ppm1 is therefore an important
350 activity and *ppm1* mutants are considerably less fit than the parent strains [10, 11]. In
351 the case of *S. coelicolor, ppm1*$^{-}$ mutants have a small colony growth phenotype and
352 are hyper-susceptible to multiple antibiotics, most of which inhibit cell wall biogenesis
353 suggesting that these mutants are pleiotropically deficient in membrane and/or
354 periplasmic function (Howlett et al, submitted). Mutants lacking Ppm1 or Pmt are also
355 resistant to phage infection and we have proposed that ϕC31 uses a glycoprotein(s)
356 as its receptor [5, 6]. We show here that depletion of enzymes in the mannose
357 metabolism pathway prior to Ppm1 display a phenotype that resembles that of the
358 *ppm1*$^{-}$ mutants. We conclude that synthesis of polyprenol phosphate mannose and
359 its subsequent role as a mannose donor in the periplasm is required for a wild type
360 antibiotic resistant phenotype.
361
362 Although the overall phenotypes of the GDP-mannose pyrophosphorylase (GMP)
363 deficient and the *manB* mutant strains resembled the *ppm1*$^{-}$ strain there were some
364 minor differences. We had difficulty in generating a GMP deficient strain. *S. coelicolor*
365 has three candidate genes that could express GMP activity and we could only obtain

366 a double *sco3039*⁻, *sco4238*⁻ mutant if *sco4238* was expressed conditionally using
367 the anhydrotetracycline-inducible *tcp830* promoter. While this is not absolute proof
368 that the GMP activity is essential in *S. coelicolor*, it would seem that some low level
369 of activity, possibly that provided by the leakiness of the repressed *tcp830* promoter
370 reading into an integrated copy of *sco4238*, is required for the simultaneous
371 interruption of both *sco3039* and *sco4238* by Tn*5062*. Similarly the insertion in
372 *sco3028* (*manB)* was obtained at very low frequency and the colonies were
373 extremely small, indicative of a requirement for both phosphomannomutase (PMM)
374 and phosphoglucomutase (PGM) activities encoded by this gene. If GMP activity is
375 essential then we would also expect PMM activity to be essential, but there may be
376 sufficient PMM activity from other closely related enzymes (such as other PGM
377 paralogues; *sco7443* or *sco4916* a possible alternative phosphomannomutase) to
378 allow growth. The more severe phenotypes of the GMP depletion mutant and the
379 *manB* mutant also suggest that GDP-mannose could be located at a metabolic
380 branch point i.e. GDP-mannose is required for polyprenol phosphate mannose
381 synthesis but also perhaps for modification into other nucleotide sugars. For
382 example, the *S. coelicolor* genome encodes a GDP-mannose dehydrogenase
383 (SCO0382) that is predicted to make GDP-mannuronate, one of the building blocks
384 in the synthesis of alginates in *Pseudomonas*. *Sco0382* lies within an operon *sco381*
385 to *sco386* that has features of an extracellular polysaccharide biosynthesis gene
386 cluster including a polyprenol dependent glycosyl transferase and various other
387 membrane proteins.
388
389 Enzyme assays with purified SCO4238 showed it to be a monofunctional GMP
390 (ManC) with a slim substrate tolerance similar to Rv3264 (previously miss-annotated

391 as *rmlA*) of *Mycobacterium* [28, 34] and in contrast to the more promiscuous ManC
392 enzymes of *E. coli* and *P. furiosis* [35, 36]. In *Mycobacterium* and in *Corynebacterium*
393 the ManC enzymes (Rv3264 and NCgl0710, respectively) provide essential supplies
394 of GDP-mannose for phosphatidyl inositol mannoside (PIM) biosynthesis and
395 lipoglycans [14].

396

397 The phenotype described here for RHB42 (*sco3028*:Tn*5062*, *manB*$^{-}$) has differences
398 and similarities to a Δ*manB* strain of *S. coelicolor* M145 that was described
399 previously [15, 16]. A notable difference is the sensitivity to antibiotics of RHB42 as
400 Yang *et al* did not detect an increase in susceptibility of their Δ*manB* strain to
401 vancomycin, bacitracin or ampicillin [16]. Whilst we cannot explain these differences
402 in phenotypes, both RHB42 and the Δ*manB* of Yang *et al* have increased pigment
403 production. Pigment production is also greatly increased in the ManC deficient
404 strains. The increase in pigment production could be indicative of the activation of
405 several stress pathways or, as discussed by Yang *et al*, could be due to the increase
406 in carbon flux through glycolysis as the pathway to GDP-mannose is blocked. The
407 *ppm1*$^{-}$ strain DT3017 has a mild pigment overproduction phenotype (data not
408 shown). Neither Yang et al, or Rajesh et al could test phage sensitivity in their
409 Δ*manB* strain as they used a Pgl^{+} strain of *S. coelicolor,* which confers ϕC31
410 resistance.

411

412 Mannose is used in other *Streptomyces spp* in the biosynthesis of antibiotics eg
413 mannopeptimycins and amphotericin [37, 38]. ManB and ManC activities are required
414 in *S. nodosus* for the glycosylation of amphotericin [38]. The identification of the
415 *manC* genes and the construction of the *manC* deficient strain could be useful in

heterologous expression and combinatorial biosynthesis of several antibiotic pathways in *S. coelicolor*.

Acknowledgements

We are grateful to Professor Mervyn Bibb for providing plasmid pIJ10257 and to Professor Paul Dyson for the provision of mutagenized cosmids.

Funding Information

This work was funded by project grants_BB/J016691 and BBS/B/05990 from the Biotechnology and Biological Sciences Research Council, UK.

Conflicts of Interest and Ethics

None

References

1. **Wang W, Ji J, Li X, Wang J, Li S et al.** Angucyclines as signals modulate the behaviors of *Streptomyces coelicolor*. *Proc Natl Acad Sci U S A* 2014;111(15):5688-5693.
2. **Nesme J, Simonet P**. The soil resistome: a critical review on antibiotic resistance origins, ecology and dissemination potential in telluric bacteria. *Environmental microbiology* 2015;17(4):913-930.
3. **D'Costa VM, McGrann KM, Hughes DW, Wright GD**. Sampling the antibiotic resistome. *Science* 2006;311(5759):374-377.
4. **Wehmeier S, Varghese AS, Gurcha SS, Tissot B, Panico M et al.** Glycosylation of the phosphate binding protein, PstS, in Streptomyces coelicolor by a pathway that resembles protein O-mannosylation in eukaryotes. *Mol Microbiol* 2009;71(2):421-433.
5. **Cowlishaw DA, Smith MCM**. Glycosylation of a *Streptomyces coelicolor* A3(2) cell envelope protein is required for infection by bacteriophage φC31. *Mol Microbiol* 2001;41(3):601-610.
6. **Cowlishaw DA, Smith MCM**. A gene encoding a homologue of dolichol phosphate-b-D mannose synthase is required for infection of *Streptomyces coelicolor* A3(2) by phage φC31. *J Bacteriol* 2002;184(21):6081-6083.

450 7. **Hoischen C, Gura K, Luge C, Gumpert J**. Lipid and fatty acid composition of
451 cytoplasmic membranes from *Streptomyces hygroscopicus* and its stable protoplast-
452 type L form. *J Bacteriol* 1997;179(11):3430-3436.
453 8. **Sandoval-Calderon M, Geiger O, Guan Z, Barona-Gomez F, Sohlenkamp**
454 **C**. A eukaryote-like cardiolipin synthase is present in *Streptomyces coelicolor* and in
455 most actinobacteria. *J Biol Chem* 2009;284(26):17383-17390.
456 9. **Guerin ME, Kordulakova J, Alzari PM, Brennan PJ, Jackson M**. Molecular
457 basis of phosphatidyl-myo-inositol mannoside biosynthesis and regulation in
458 mycobacteria. *J Biol Chem* 2010;285(44):33577-33583.
459 10. **Gibson KJ, Eggeling L, Maughan WN, Krumbach K, Gurcha SS et al.**
460 Disruption of Cg-Ppm1, a polyprenyl monophosphomannose synthase, and the
461 generation of lipoglycan-less mutants in *Corynebacterium glutamicum*. *J Biol Chem*
462 2003;278(42):40842-40850.
463 11. **Rana AK, Singh A, Gurcha SS, Cox LR, Bhatt A et al.** Ppm1-encoded
464 polyprenyl monophosphomannose synthase activity is essential for lipoglycan
465 synthesis and survival in mycobacteria. *PloS one* 2012;7(10):e48211.
466 12. **Liu CF, Tonini L, Malaga W, Beau M, Stella A et al.** Bacterial protein-O-
467 mannosylating enzyme is crucial for virulence of *Mycobacterium tuberculosis*. *P Natl*
468 *Acad Sci USA* 2013;110(16):6560-6565.
469 13. **Mahne M, Tauch A, Puhler A, Kalinowski J**. The Corynebacterium
470 glutamicum gene pmt encoding a glycosyltransferase related to eukaryotic protein-O-
471 mannosyltransferases is essential for glycosylation of the resuscitation promoting
472 factor (Rpf2) and other secreted proteins. *FEMS Microbiol Lett* 2006;259(2):226-233.
473 14. **Mishra AK, Krumbach K, Rittmann D, Batt SM, Lee OY et al.** Deletion of
474 manC in Corynebacterium glutamicum results in a phospho-myo-inositol mannoside-
475 and lipoglycan-deficient mutant. *Microbiology* 2012;158(Pt 7):1908-1917.
476 15. **Rajesh T, Song E, Lee BR, Park SH, Jeon JM et al.** Increased sensitivity to
477 chloramphenicol by inactivation of *manB* in *Streptomyces coelicolor*. *Journal of*
478 *microbiology and biotechnology* 2012;22(10):1324-1329.
479 16. **Yang YH, Song E, Park SH, Kim JN, Lee K et al.** Loss of
480 phosphomannomutase activity enhances actinorhodin production in *Streptomyces*
481 *coelicolor*. *Applied microbiology and biotechnology* 2010;86(5):1485-1492.
482 17. **Green RM, Sambrook J**. *Molecular Cloning: A laboratory Manual*, Fourth
483 Edition ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press;
484 2012.
485 18. **Gust B, Challis GL, Fowler K, Kieser T, Chater KF**. PCR-targeted
486 *Streptomyces* gene replacement identifies a protein domain needed for biosynthesis
487 of the sesquiterpene soil odor geosmin. *Proc Natl Acad Sci U S A* 2003;100(4):1541-
488 1546.
489 19. **Jyothikumar V, Klanbut K, Tiong J, Roxburgh JS, Hunter IS et al.**
490 Cardiolipin synthase is required for *Streptomyces coelicolor* morphogenesis. *Mol*
491 *Microbiol* 2012;84(1):181-197.
492 20. **Rodriguez-Garcia A, Combes P, Perez-Redondo R, Smith MCM**. Natural
493 and synthetic tetracycline-inducible promoters for use in the antibiotic-producing
494 bacteria *Streptomyces*. *Nucleic Acids Res* 2005;33(9):e87.
495 21. **Fayed B, Younger E, Taylor G, Smith MC**. A novel Streptomyces spp.
496 integration vector derived from the *S. venezuelae* phage, SV1. *BMC biotechnology*
497 2014;14:51.
498 22. **Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA**. *Practical*
499 *Streptomyces Genetics*. Norwich: The John Innes Foundation; 2000.

23. **Sinclair RB, Bibb MJ**. The repressor gene (c) of the *Streptomyces* temperate phage ϕC31: nucleotide sequence, analysis and functional cloning. *Mol Gen Genet* 1988;213(2-3):269-277.
24. **Bradford MM**. A rapid and sensitive method for the quantitation of microgram quantities of protein, utilising the principal of protein-dye binding. *Anal Biochem* 1976;72:248-254.
25. **Pelissier MC, Lesley SA, Kuhn P, Bourne Y**. Structural insights into the catalytic mechanism of bacterial guanosine-diphospho-D-mannose pyrophosphorylase and its regulation by divalent ions. *J Biol Chem* 2010;285(35):27468-27476.
26. **Sousa SA, Moreira LM, Leitao JH**. Functional analysis of the B*urkholderia cenocepacia* J2315 BceAJ protein with phosphomannose isomerase and GDP-D-mannose pyrophosphorylase activities. *Applied microbiology and biotechnology* 2008;80(6):1015-1022.
27. **Fernandez-Martinez LT, Del Sol R, Evans MC, Fielding S, Herron PR et al.** A transposon insertion single-gene knockout library and new ordered cosmid library for the model organism *Streptomyces coelicolor* A3(2). *Antonie Van Leeuwenhoek* 2011;99(3):515-522.
28. **Ma Y, Stern RJ, Scherman MS, Vissa VD, Yan W et al.** Drug targeting *Mycobacterium tuberculosis* cell wall synthesis: genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. *Antimicrob Agents Chemother* 2001;45(5):1407-1416.
29. **Bedford DJ, Laity C, Buttner MJ**. Two genes involved in the phase-variable ϕC31 resistance mechanism of *Streptomyces coelicolor* A3(2). *J Bacteriol* 1995;177(16):4681-4689.
30. **Dobos KM, Khoo KH, Swiderek KM, Brennan PJ, Belisle JT**. Definition of the full extent of glycosylation of the 45-kilodalton glycoprotein of *Mycobacterium tuberculosis*. *J Bacteriol* 1996;178(9):2498-2506.
31. **Michell SL, Whelan AO, Wheeler PR, Panico M, Easton RL et al.** The MPB83 antigen from Mycobacterium bovis contains O-linked mannose and (1-->3)-mannobiose moieties. *J Biol Chem* 2003;278(18):16423-16432.
32. **Mishra AK, Driessen NN, Appelmelk BJ, Besra GS**. Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in *Mycobacterium tuberculosis* physiology and host-pathogen interaction. *FEMS Microbiol Rev* 2011;35(6):1126-1157.
33. **Besra GS, Morehouse CB, Rittner CM, Waechter CJ, Brennan PJ**. Biosynthesis of mycobacterial lipoarabinomannan. *J Biol Chem* 1997;272(29):18460-18466.
34. **Ning B, Elbein AD**. Purification and properties of mycobacterial GDP-mannose pyrophosphorylase. *Arch Biochem Biophys* 1999;362(2):339-345.
35. **Mizanur RM, Pohl NL**. Phosphomannose isomerase/GDP-mannose pyrophosphorylase from *Pyrococcus furiosus*: a thermostable biocatalyst for the synthesis of guanidinediphosphate-activated and mannose-containing sugar nucleotides. *Organic & biomolecular chemistry* 2009;7(10):2135-2139.
36. **Yang YH, Kang YB, Lee KW, Lee TH, Park SS et al.** Characterization of GDP-mannose pyrophosphorylase from *Escherichia coli* O157 : H7 EDL933 and its broad substrate specificity. *J Mol Catal B-Enzym* 2005;37(1-6):1-8.
37. **Magarvey NA, Haltli B, He M, Greenstein M, Hucul JA**. Biosynthetic pathway for mannopeptimycins, lipoglycopeptide antibiotics active against drug-

550 resistant gram-positive pathogens. *Antimicrob Agents Chemother* 2006;50(6):2167-
551 2177.
552 38. **Nic Lochlainn L, Caffrey P**. Phosphomannose isomerase and
553 phosphomannomutase gene disruptions in *Streptomyces nodosus*: impact on
554 amphotericin biosynthesis and implications for glycosylation engineering. *Metabolic*
555 *engineering* 2009;11(1):40-47.
556 39. **Hong HJ, Hutchings MI, Hill LM, Buttner MJ**. The role of the novel Fem
557 protein VanK in vancomycin resistance in Streptomyces coelicolor. *J Biol Chem*
558 2005;280(13):13055-13061.
559 40. **MacNeil DJ**. Characterization of a unique methyl-specific restriction system in
560 Streptomyces avermitilis. *J Bacteriol* 1988;170(12):5607-5612.
561

562

563 **Legends to Figures**

564 **Figure 1. The GDP-mannose biosynthesis pathway in *Streptomyces coelicolor*.**

565

566 **Figure 2. GDP-mannose pyrophosphorylases in *Streptomyces coelicolor*** A.
567 Domain structures for *S. coelicolor* genes with putative GDP-mannose
568 phosphorylase activity. B. Pigment overproduction in *sco4238, sco3039* double
569 mutants. Strain RH2213 (*sco4239::Tn5062spec*, *sco3039::Tn5062,* pRH01 encoding
570 inducible *sco4238)* overproduced blue pigment on supplemented minimal medium
571 solid (SMMS) agar in the absence of anhydrotetracycline (ATC) but not in the
572 presence of 0.5 μg/ml ATC.

573

574 **Figure 3*. Streptomyces coelicolor* strains depleted in GDP mannose**
575 **pyrophosphorylase activity are partially resistant to ϕC31 and are hyper-**
576 **susceptible to some antibiotics** A. Spores of the indicated *S. coelicolor* strains
577 were streaked from an area free from ϕC31 to an area inoculated with $1x10^7$ pfu
578 ϕC31 on Difco nutrient agar plates with or with the supplementation of 0.5 μg/ml
579 anhydrotetracycline (ATC). RH2213 (*sco4239::Tn5062*^{spec}, *sco3039::Tn5062,* pRH01

580 encoding inducible *sco4238)* showed conditional phage resistance growing only in
581 the absence of ATC. For comparison the phage resistant phenotype of the *ppm1*$^-$
582 mutant (DT3017), the parent strain (J1929) and the strains with single mutations in
583 the *manC* candidate genes, *sco3039* and *sco4238*, (SKA211 and RH25,
584 respectively). *B.* RH2213 showed increased susceptibility to antibiotics in the
585 absence of ATC but not in the presence of ATC. This phenotype is comparable to the
586 antibiotic hyper-susceptible phenotype of the *ppm1*$^-$ mutant (DT3017). Results show
587 the mean diameter of the disc diffusion inhibition zones from at least 3 replicates.
588 Antibiotics were all used at 4 μg/disc with the exception of ampicillin that was used
589 at 40 μg/disc.

590

591 **Figure 4. Kinetics of GDP-mannose pyrophosphorylase activity of SCO4238.**
592 Dependence of initial velocity of SCO4238 GMP activity with increasing
593 concentration of mannose-1-phosphate (A) and mannose-6-phosphate (B). C. Kinetic
594 parameters Km, n_H and Vmax for the two sugar phosphate substrates.

595

596 **Figure 5. Phenotypes of the *manB*$^-$ (*sco3028*::Tn*5062*) mutants.** A. Extreme *s*mall
597 colony phenotype (left) and resistance to phage ϕC31 (right) in the RHB42
598 (*sco3028*::Tn*5062*) mutant strains. The poor growth of RHB42 was complemented
599 with an additional copy of *sco3028* (RHB4212) or the *E. coli* gene *cpsG* (*manB*
600 homologue; RHB4211) but not *pgm* from *E. coli* (encoding phosphglucomutase;
601 RHB4214). The ϕC31 resistance in RHB42 reverted to phage sensitivity in the
602 complemented strains RHB4211 and RHB4212. B. RHB42 has increased
603 susceptibility to antibiotics resembling the phenotype of the *ppm1*$^-$ mutant (DT3017).
604 Antibiotic susceptibility could be complemented with an additional copy of *sco3028*

605 and *E. coli cpsG* but not *pgm* from *E. coli*. C. Increased pigment production in RH42
606 compared to the parental strain, J1929. This phenotype was complemented by
607 additional copy of *sco3028* and *E. coli cpsG* but not *pgm* from *E. coli*.
608
609
610

611 Table 1. Bacteria, plasmids and cosmids

Plasmid Name	Description	References
pAVIIb	Integrating vector with *tcp830* promoter and *Tetris* cassette	[21]
pRH01	*sco4238* in pAV11b	This study
pDT16	*sco1423 (ppm1)* in pSET152	[6]
pDT10	*sco3154 (pmt)* in pSET152	[5]
pET21a	Overexpression vector containing HIS_6-tag, T7 promotor	Merck Chemicals
pRH06	*sco3039* in pET21a	This study
pRH07	*sco4238* in pET21a	This study
pIJ10257	Integrating vector with constitutive promoter *ermEp**	[39]
pRH11	*cpsG* in pIJ10257	This study
pRH12	*sco3028* in pIJ10257	This study
pRH14	*pgm* in pIJ10257	This study
Cosmid	**Description**	**References**
St1A8A.1.B09	SCO1388::Tn*5062* at nt 572	[27]
StD8A.2.D12	SCO4238::Tn*5062* at nt 69	[27]
StE34.1.G05	SCO3039::Tn*5062* at nt 155	[27]
StE34.1.B03	SCO3028::Tn*5062* at nt 590	[27]
StD8A.2.D12^{spec}	StD8A.2.D12 with *sco4238*::Tn*5062*^{spec}	This study
St1A8A.1.B09^{hyg}	St1A8A.1.B09 with *sco1388*::Tn*5062*^{hyg}	This study
***Streptomyces* strain**	**Genotype**	**References**
M145	Prototroph	[22]
J1929	*pglY* mutant	[29]
DT3017	*ppm1*^{E218V} mutant	[6]
DT1020	*ppm1*^{H116D} mutant	[6]
DT1029	*ppm1*^{S163L} mutant	[6]
DT1025	*pmt,* frameshift from A121	[5]
DT2008	*pmt*$^{-}$	[5]

SKA211	*sco3039*::Tn5062	This study
SKA311	*sco4238*::Tn5062	This study
RH501	*sco1388*::Tn5062	This study
RH25	*sco4238*::Tn5062^{spec}	This study
RH221	*sco4238*::Tn5062^{spec}, pRH01	This study
RH2213	*sco4238*::Tn5062^{spec} *sco3039*::Tn5062, pRH01	This study
RHB42	*sco3039*::Tn5062	This study
RHB4211	*sco3028*::Tn5062, pRH11	This study
RHB4212	*sco3028*::Tn5062, pRH12	This study
RHB4214	*sco3028*::Tn5062, pRH14	This study
***E.coli* strain**	**Genotype**	**References**
ET12567(pUZ8002)	*dam- dcm- hsdS*, RP4 transfer genes	[40]
BL21 (DE3)	*lon, ompT, gal, hsdS*, λDE3	[17]
DH5α	F- Φ80*lac*ZΔM15 Δ(*lac*ZYA-*arg*F) U169 *rec*A1 *end*A1 *hsd*R17 (rk-, mk+) *pho*A *sup*E44 λ-*thi*-1 *gyr*A96 *rel*A1	[17]

612

613

Click here to download Figure GDP-mannose pathway.pdf



Figure 1

 Click here to download Figure manC_doms&antibiotics.pdf

A



B



Figure 2

Figure 3

Click here to download Figure phage&DDAs manC mutants_rev.pdf

A



B



Figure 3

Click here to download Figure kinetics 4238.pdf



Substrate	Km (mM)	n_H	Vmax (mM/min/mg protein)
Man-1-P	0.18 ± 0.03	1.77 ± 0.27	0.79 ± 0.04
Man-6-P	0.30 ± 0.12	0.79 ± 0.22	0.34 ± 0.04

Figure 4

Figure 5

Click here to download Figure manB all datav2_rev.pdf

A



B



C



Figure 5

Click here to download Supplementary Material Files combined suppl info ManC_B.pdf

M145 wt	MD202 *sco3028*$^-$	MD202 *sco3028*$^-$, *cpsG*$^+$	MD202 *sco3028*$^-$,*sco3028*$^+$	MD202 *sco3028*$^-$, *pgm*$^+$
	MB92 *sco3028*$^-$	MB92 *sco3028*$^-$, *cpsG*$^+$	MB92 *sco3028*$^-$,*sco3028*$^+$	MB92 *sco3028*$^-$,*pgm*$^+$
	JD182 *sco3028*$^-$	JD182 *sco3028*$^-$, *cpsG*$^+$	JD182 *sco3028*$^-$,*sco3028*$^+$	JD182 *sco3028*$^-$,*pgm*$^+$



Figure S1



Figure S2

Supplementary Figure Legends. Howlett *et al.*

Figure S1. Extreme small colony phenotype of various *manB*$^-$ strains of *S. coelicolor*. MD202 is a derivative of *S. coelicolor* M145 containing *sco3028::Tn5062* at nt 590 derived from cosmid StE34.1.B03 (1, 2). MB92 and JD182 are derivatives of *S. coelicolor* M145 and J1929, respectively, containing *sco3028::Tn5062* at nt 576 derived from cosmid StE34.2.D03 (1, 2). In each case a transposon insertion in *sco3028*, (encoding ManB) confers an extreme small colony phenotype. The phenotype can be fully complemented by introduction of a wild type copy of *sco3028* (*sco3028*$^+$ in pRH12), *E. coli cpsG* (encoding ManB in pRH11) but not by *E. coli pgm* (encoding phosphoglucomutase, pRH14).

Figure S2. Antibiotic hyper-susceptible phenotype of various *manB*$^-$ strains *of S. coelicolor*. Strains are as described in the legend to Figure S2. For comparison the antibiotic susceptibility profiles of the parent strains J1929 and M145 and that of the *ppm1*$^-$ strain DT3017 are also shown.

References

1. Bishop A, Fielding S, Dyson P, Herron P. Systematic insertional mutagenesis of a streptomycete genome: a link between osmoadaptation and antibiotic production. Genome Res. 2004;14(5):893-900.
2. Fernandez-Martinez LT, Del Sol R, Evans MC, Fielding S, Herron PR, Chandra G, et al. A transposon insertion single-gene knockout library and new ordered cosmid library for the model organism Streptomyces coelicolor A3(2). Antonie Van Leeuwenhoek. 2011;99(3):515-22.

Table S1. Oligonucleotides for Howlett, Read *et al*,

Primer	Sequence	Use
RH11	TCTAGAGACGTCGATATCATGACCGATCCGAACGCC GCGTCC	*sco4238* F Infusion; pRH01
RH12	CATGCATGATCAGATATCTCAGCGGCCGGACAGGG CCG	*sco4238* R Infusion; pRH01
RH71	GACGCCCATATGACAGAAGCGATCCTCCTG	*sco3039* (NdeI); pRH06
RH72	CGTTACAAGCTTCGTGTCCGGTGAGAAGCG	*sco3039* (HindIII); pRH06
RH73	GGCGCCCATATGACCGATCCGAACGCCGCGTC	*sco4238* (NdeI); pRH07
RH74	GTACCTCGAGGCGGCCGGACAGGGCCG	*sco4238* (XhoI); pRH07
RH91	ACAGGAGGCCCCATATGGCTGCTGATCTGTCGCAG	*sco3028* F Infusion; pRH12
RH92	ACTCGAGATCTCATATGTCACGCCCGGATGATCGCC	*sco3028* R Infusion; pRH12
RH93	ACAGGAGGCCCCATATGAAAAAATTAACCTGCTTT	*cpsG(manB)* F Infusion; pRH11
RH94	ACTCGAGATCTCATATGTTACTCGTTCAGCAACG	*cpsG(manB)* R Infusion; pRH11
RH140	ACAGGAGGCCCCATATGGCAATCCACAATCGTGC	*pgm* F Infusion; pRH14
RH141	ACTCGAGATCTCATATGTTACGCGTTTTTCAGAA	*pgm* R Infusion; pRH14